Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST

NCT02638766 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: regorafenib

Sponsor

Grupo Espanol de Investigacion en Sarcomas

Collaborators

[object Object]